NCT00533585 - BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions

Lung Cancer

Interventions

DRUG

BAY 43-9006

Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.

DRUG

Paclitaxel

200 mg/m\^2 By Vein Over 3 Hours on Day 1.

DRUG

Carboplatin

Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.

DRUG

Bevacizumab

Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston